Ipamorelin and GHRP-6 both stimulate growth hormone release through the ghrelin receptor, but they're frequently contrasted specifically because of a real, documented pharmacological difference in selectivity.
The Selectivity Difference
Research on ipamorelin, detailed in this site's dedicated guide, has generally found it produces less cortisol and prolactin elevation compared to older GHRPs like GHRP-6, at comparable doses for growth hormone stimulation. This is a genuine pharmacological distinction with research backing, not just marketing language, and it's the primary reason ipamorelin is often positioned as the more refined option within this specific peptide family.
The Appetite Stimulation Difference
GHRP-6 has documented appetite-stimulating effects tied to its activity on the ghrelin receptor, an effect that's actually shared to some degree by the whole GHRP class through this same receptor, but appears more pronounced for GHRP-6 specifically in available research and user reports. This is directly relevant for anyone using either compound with a body composition or fat-loss goal in mind, since appetite stimulation can work against that objective.
Evidence Base Comparison
GHRP-6 has a longer research history simply due to being an older compound, giving it a somewhat larger, if still older and limited, body of literature. Ipamorelin's research, while more recent and specifically focused on demonstrating its selectivity advantage, is still limited in scale compared to a fully trialed pharmaceutical drug.
Neither Is FDA-Approved
Despite their pharmacological differences, both compounds share the same basic regulatory status: neither is FDA-approved, and neither is eligible for pharmacy compounding as a stand-alone substance, meaning both are available only through the unregulated research-chemical market regardless of their relative selectivity profile.
The Bottom Line
The selectivity and appetite-effect differences between ipamorelin and GHRP-6 are real and research-backed, distinguishing them meaningfully from each other within the same peptide family. But that internal comparison shouldn't be mistaken for either compound having cleared the much higher bar of human clinical trials or regulatory approval, which neither has.
Why Some Users Still Prefer GHRP-6
Despite ipamorelin's cleaner selectivity profile, some users and even some research contexts favor GHRP-6 specifically because of its stronger appetite-stimulating effect, when the goal is caloric intake support rather than fat loss, illustrating that "more selective" isn't universally "better," it depends entirely on which of a compound's several effects actually align with an individual's specific goal.
Neither Comparison Point Should Be Overstated
It's worth keeping the scale of this comparison in perspective: both compounds remain in the same broad evidence category relative to the fully trialed drugs discussed elsewhere on this site, meaning the selectivity and appetite differences described here are meaningful within the GHRP family specifically, not evidence that either compound has cleared a substantially higher overall bar of proven human safety and efficacy.